Nature Communications (Jan 2024)

Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells

  • Caroline Passaes,
  • Delphine Desjardins,
  • Anaïs Chapel,
  • Valérie Monceaux,
  • Julien Lemaitre,
  • Adeline Mélard,
  • Federico Perdomo-Celis,
  • Cyril Planchais,
  • Maël Gourvès,
  • Nastasia Dimant,
  • Annie David,
  • Nathalie Dereuddre-Bosquet,
  • Aurélie Barrail-Tran,
  • Hélène Gouget,
  • Céline Guillaume,
  • Francis Relouzat,
  • Olivier Lambotte,
  • Jérémie Guedj,
  • Michaela Müller-Trutwin,
  • Hugo Mouquet,
  • Christine Rouzioux,
  • Véronique Avettand-Fenoël,
  • Roger Le Grand,
  • Asier Sáez-Cirión

DOI
https://doi.org/10.1038/s41467-023-44389-3
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 19

Abstract

Read online

Abstract HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control, but the circumstances and mechanisms leading to this outcome remain unclear. Here we evaluate the impact of early (week 4) vs. late (week 24 post-infection) treatment initiation in SIVmac251-infected male cynomolgus macaques receiving 2 years of therapy before analytical treatment interruption. We show that early treatment strongly promotes post-treatment control, which is not related to a lower frequency of infected cells at treatment interruption. Rather, early treatment favors the development of long-term memory CD8+ T cells with enhanced proliferative and SIV suppressive capacity that are able to mediate a robust secondary-like response upon viral rebound. Our model allows us to formally demonstrate a link between treatment initiation during primary infection and the promotion of post-treatment control and provides results that may guide the development of new immunotherapies for HIV remission.